Cerebral Palsy Treatment Market Size, Share, and Industry Analysis, By Type (Spastic Cerebral Palsy, Dyskinetic Cerebral Palsy, Ataxic Cerebral Palsy, and Others), By Treatment (Botulinum Toxin, Anticholinergics, Anticonvulsants, Antidepressants, Muscle Relaxants, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Cerebral palsy (CP) is a congenital disorder that affects the person's ability to move, maintain balance & posture. This is a lifelong condition mainly caused by damage in the developing brain, most commonly before birth. According to the area of the brain affected, cerebral palsy is divided into several types, such as spastic cerebral palsy, dyskinetic CP, ataxic CP, hypotonic CP, and mixed CP.

The symptoms associated with cerebral palsy include a lack of muscle coordination, tremors, neurological issues (seizures and intellectual disabilities), and difficulty in walking. Moreover, treatment for cerebral palsy typically involves physical therapies and medications, and, in some cases, surgery can be done to treat cerebral palsy.

• For example, medications such as Dysport (abobotulinumtoxinA) are used for the treatment of lower limb spasticity for patients with cerebral palsy.
• Furthermore, along with the medications, some healthcare professionals provide physical therapy, such as muscle training and exercises to enhance a child's strength, flexibility, balance, motor development, and mobility.
• Moreover, surgical procedures are also a part of treatment for cerebral palsy. Surgery can correct bone changes caused by spasticity and reduce muscle tightness to enhance a patient's movement.

In addition, the growing prevalence of cerebral palsy and the rising research and development activities for developing effective therapeutics for treating cerebral palsy are some of the factors expected to boost the market growth during the forecast period.

• For instance, as per the data provided by SCOPE U.K. in June 2023, about one in every 400 children in the U.K. are affected with cerebral palsy. This means that around 1,800 children are diagnosed with cerebral palsy every year. Consequently, the condition's high prevalence has led to a rising demand for its treatments, prompting research and development activities, thereby driving significant market growth.
• Similarly, as per the data provided by Clinicaltrials.gov, in December 2022, a study was conducted by Jazz Pharmaceuticals to check the efficacy of Sativex for the treatment of spastic cerebral palsy in a population of children and adolescents aged from 8 to 18 years, and it was found to be safe and effective. It is anticipated that the topline findings of these studies are anticipated to support the introduction of new medicines and thus drive market growth.

In addition, a research study published by BMC Neurology in March 2022 indicated that the intrathecal injection of umbilical cord blood mononuclear cells (UCB-MNC) was safe and effective in treating children with cerebral palsy. Thus, the safety and efficacy of such therapies for cerebral palsy are expected to fuel market growth due to increased adoption rates.

Therefore, the significant growth of the market is expected to be driven by factors such as increasing safety and efficacy of treatments and increasing prevalence of disease, among others.

The COVID-19 pandemic had a negative impact on the global cerebral palsy treatment market in 2020. This was mainly due to the fact that lack of access to health services, limited regular cerebral palsy health check-ups, and limited access to medical equipment.

• For instance, as per the data provided by the National Bobath Cerebral Palsy Center in 2023, nearly 59% of adults and 42% of children lacked access to adequate healthcare services to fully meet their needs. Also, 41% of adults and 11% of children faced a scarcity of medical equipment to support their needs due to cerebral palsy.

Segmentation

Key Insights

The following key insights are covered in the report:

• Prevalence of Cerebral Palsy, By Key Countries, 2022/2023
• Pipeline Analysis By Key Players
• Key Industry Developments - Mergers, Acquisitions, and Partnerships
• Overview: Alternative Therapies for Cerebral Palsy
• Impact of COVID-19 on the Global Cerebral Palsy Treatment Market

Analysis by Type

Based on the type, the market can be segmented into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and others.

The spastic cerebral palsy segment held a significant market share in 2023. The growth of the segment is attributed to the fact that around 77.0% of the total cerebral palsy patients are suffering from spastic cerebral palsy.

• For instance, as per the data provided by cerebralpalsyguide.com in November 2023, nearly 75.0% to 85.0% of children with cerebral palsy have spastic CP.

Also, increasing initiatives by researchers from different universities for the development of medicines for the treatment of spastic CP, supporting the segment's growth during the forecast period.

• For instance, in August 2020, the Universitaire Ziekenhuizen KU Leuven initiated an interventional study that investigated the effect of integrated Botulinum Neurotoxin A in Children with spastic cerebral palsy.

Furthermore, the dyskinetic cerebral palsy segment is anticipated to grow significantly in the coming years. The segment growth is mainly driven by the fact that several industry players have initiated clinical trials for the development of medicines for the treatment of dyskinetic cerebral palsy.  

• For instance, as per the data provided by ClinicalTrials.gov, Neurocrine Biosciences, Inc. initiated a phase 3 clinical trial in April 2022 to evaluate the efficacy of Valbenazine for the treatment of dyskinetic cerebral palsy.

Furthermore, the other segment held a considerable market share in 2023, mainly due to the rising incidence of mixed cerebral palsy globally.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the cerebral palsy market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant market share in 2023 and is expected to exhibit a substantial CAGR during the forecast period. The region's growth is mainly due to the growing prevalence of cerebral palsy, leading to the increasing demand for medications used to treat this disease in the North American region. Along with this, a strong pipeline of cerebral palsy medications under development by the operating players in the region further supports regional growth in the near future.

• For example, as per the data provided by the Autism and Developmental Disabilities Monitoring (ADDM) Network in November 2023, cerebral palsy (CP) affected about 1.0 million people in the U.S. The prevalence of CP in the U.S. is 1 out of 345 children (or 3 per 1,000 {8-year-old children}).
• Similarly, as per the data provided by Congress.gov in March 2022, each year, over 10,000 babies are diagnosed with cerebral palsy in the U.S. The demand for its therapeutic products is growing due to the prevalence of cerebral palsy in this country. Therefore, the pharmaceutical industry is investing heavily in this therapeutic area, which will significantly impact the market. Therefore, pharmaceutical companies are investing heavily in this therapeutic area, which will significantly impact the market.

Furthermore, the European region accounted for a considerable market share in 2023. Rising investments in the development of technologically advanced healthcare facilities for treating cerebral palsy are one of the factors contributing to market growth.

• For instance, in April 2022, Jupiter Lifeline Hospitals revealed its plan to establish an advanced neuro-rehabilitation center in the U.K. with an investment of approximately 50.0 million pounds (USD 62.2 million). The proposed rehabilitation center is anticipated to accommodate 100 inpatients. It will serve individuals with conditions such as cerebral palsy, traumatic brain injury, progressive and non-progressive neurological disorders, and spinal cord injuries, offering them significant benefits.

Key Players Covered

The report includes the profiles of key players, such as Neurocrine Biosciences, Inc., Revance Therapeutics, Inc., Pfizer Inc., and Ipsen Pharma.

Key Industry Developments

• In January 2024, Neurotech International received approval from the Human Research Ethics Committee (HREC) and clearance from the Therapeutic Goods Administration (TGA) to initiate a Phase I/II clinical trial of NTI164 for the treatment of cerebral palsy (CP).
• In July 2023, Cerebral Palsy Alliance (CPA) unveiled a new brand campaign in collaboration with Cummins & Partners. The campaign, titled 'A Life Changing Movement,' showcased how CPA supports the exploration of the potential of children and adults with cerebral palsy.
• In May 2023, the Cerebral Palsy Foundation collaborated with University College Cork, Trinity College Dublin, and the Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences to initiate a program aimed at revolutionizing cerebral palsy care in Ireland. Under the program, approximately 150 babies in Ireland are diagnosed with cerebral palsy every year.
• In March 2022, the Cerebral Palsy Research Programme Act, introduced by Congressmen Steve Cohen & Brian Fitzpatrick, and Emanuel Cleaver, proposed creating a cerebral palsy research program within the centers for Disease Control and Prevention (CDC). This initiative would establish the first-ever dedicated federal funding source for cerebral palsy research.
• In February 2022, Cerebral Palsy Alliance Research Foundation (CPA) and Hearts & Minds Investments Limited forged a partnership to foster innovative research to revolutionize newborn intensive care worldwide. This collaboration aims to reduce the occurrence and severity of cerebral palsy and other lifelong issues in children by supporting Australia's leading neonatologists and bioengineers in their work.